Search results for "CLINICAL TRIALS"

showing 10 items of 490 documents

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

2010

Background: Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and development costs are exerting pressure on the drug development pipeline. The result is a de-emphasis of exploratory research, particularly independent academic research, despite its proven value in identifying new drug targets and developing innovative cancer therapies. Design: An expert panel assembled by the Biotherapy Development Association-a nonprofit international forum for academic and indus…

Oncologymedicine.medical_specialtyacademic research Clinical Trials Directive drug development investigator-initiated trials oncologytargeted therapiesSettore MED/06 - Oncologia MedicaeducationExploratory researchReviewsAntineoplastic AgentsPatient advocacyInternal medicineNeoplasmsmedicineHumanshealth care economics and organizationsReimbursementLicensureGovernmentClinical Trials as Topicbusiness.industryLegislatureHematologyResearch PersonnelClinical trialOncologyDrug developmentbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).

2022

Abstract Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti‐drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ADA can only be observed post randomization, and imbalances in baseline prognostic factors can confound the interpretation of ADA impact. We applied methodology to account for the confoundin…

Oncologymedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRandomizationCombination therapyDatabases FactualMEDLINERM1-950Antibodies Monoclonal HumanizedGeneral Biochemistry Genetics and Molecular BiologyArticleAtezolizumabimmune system diseasesInternal medicineNeoplasmsmedicineHumansGeneral Pharmacology Toxicology and PharmaceuticsAdverse effectImmune Checkpoint InhibitorsClinical Trials as Topicbusiness.industryGeneral NeuroscienceImmunogenicityResearchConfoundingnutritional and metabolic diseaseshemic and immune systemsGeneral MedicineArticlesAntibodies Monoclonal Humanized/immunology; Antibodies Monoclonal Humanized/pharmacokinetics; Antibodies Neutralizing/immunology; Antibodies Neutralizing/metabolism; Clinical Trials as Topic; Databases Factual; Humans; Immune Checkpoint Inhibitors/immunology; Immune Checkpoint Inhibitors/pharmacokinetics; Neoplasms/drug therapy; Safety; Treatment OutcomeAntibodies NeutralizingClinical trialenzymes and coenzymes (carbohydrates)Treatment OutcomeTherapeutics. PharmacologyPublic aspects of medicineRA1-1270SafetybusinessClinical and translational science
researchProduct

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.

2009

Background: Cetuximab and panitumumab, mAbs targeting EGFR, are registered for metastatic colorectal carcinoma (mCRC) patients whose tumors express EGFR as determined by immunohistochemistry. However, this method is not predictive of treatment efficacy. KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene, encodes a small G-protein that functions downstream of EGFR-induced signalling. Objective/Methods: To examine KRAS mutations as predictive factors of response to anti-EGFR mAbs using recently published data. Results/conclusions: Several retrospective studies show that efficacy of these mAbs is confined to patients with wild type KRAS and genotyping of tumors should be consi…

Oncologymedicine.medical_specialtymedicine.drug_classColorectal cancerClinical BiochemistryPopulationCetuximabMonoclonal antibodymedicine.disease_causeAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsDrug DiscoverymedicinePanitumumabAnimalsHumansKRAScolorectal carcinomaeducationneoplasmsGenotypingPharmacologyeducation.field_of_studyClinical Trials as TopicCetuximabbusiness.industryPanitumumabAntibodies Monoclonalmedicine.diseasedigestive system diseasesErbB ReceptorsMutationCancer researchras ProteinsImmunohistochemistryKRASbusinessColorectal Neoplasmsmedicine.drugExpert opinion on biological therapy
researchProduct

Effects of a Home‐Based Physical Rehabilitation Program on Tibial Bone Structure, Density, and Strength After Hip Fracture: A Secondary Analysis of a…

2019

Abstract Weight‐bearing physical activity may decrease or prevent bone deterioration after hip fracture. This study investigated the effects of a home‐based physical rehabilitation program on tibial bone traits in older hip fracture patients. A population‐based clinical sample of men and women operated for hip fracture (mean age 80 years, 78% women) was randomly assigned into an intervention (n = 40) and a standard care control group (n = 41) on average 10 weeks postfracture. The intervention group participated in a 12‐month home‐based rehabilitation intervention, including evaluation and modification of environmental hazards, guidance for safe walking, nonpharmacological pain management, m…

Orthopedic surgeryluustoINJURY/FRACTURE HEALINGexerciseagingluuEXERCISEDiseases of the musculoskeletal systemOriginal ArticlesliikuntaAGINGikääntyminenmurtumatRC925-935BONE QCT/μCTkliiniset kokeetOriginal ArticleRD701-811injury/fracture healingCLINICAL TRIALSJBMR Plus
researchProduct

Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis.

2020

Abstract Background Throughout the 5000-year history of China, more than 300 epidemics were recorded. Traditional Chinese herbal medicine (TCM) has been used effectively to combat each of these epidemics’ infections, and saved many lives. To date, there are hundreds of herbal TCM formulae developed for the purpose of prevention and treatment during epidemic infections. When COVID-19 ravaged the Wuhan district in China in early January 2020, without a deep understanding about the nature of COVID-19, patients admitted to the TCM Hospital in Wuhan were immediately treated with TCM and reported later with >90% efficacy. Approach We conducted conduct a systematic survey of various TCM herbal pre…

PTGS2 Prostaglandin-endoperoxide synthase 2BattleAIV avian influenza virusCoV coronavirusPharmaceutical ScienceiNOS nitric oxide synthaseViral infection0302 clinical medicinePA patchouli alcoholSARS Severe Acute Respiratory SyndromeSMD Sheganmahuang decoctionDrug DiscoveryPandemicIL InterleukinMedicine Chinese TraditionalALI acute lung injuriesmedia_commonCOVID-19 coronavirus disease 2019MXSG Ma xing shi gan decoction0303 health sciencesTNF tumor necrosis factorClinical Trials as TopicCCL2 CC chemokine ligand 2FM1 FM1 coronavirusICU intensive care unitc-AMP cyclic adenosine phosphateHIV human immunodeficiency virus030220 oncology & carcinogenesisCOX-2 cyclooxygenase-2Molecular MedicineHerbal preparationsMedicinal herbsAbbreviations: ACE2 angiotensin-converting enzyme IITCM traditional Chinese medicineHSV-1 herpes simplex virus 1CASP3 caspase 3medicine.medical_specialtyChinaCoronavirus disease 2019 (COVID-19)Systematic surveymedia_common.quotation_subjectJEV Japanese encephalitis virusNF-κB nuclear factor kappa B cellsAntiviral AgentsArticleWHO World Health Organization03 medical and health sciencesIEC-6 rat intestinal epithelial cell line 6SOD superoxide dismutaseCDC Center for Disease Control and PreventionmedicineAVP arginine vasopressinPGE2 prostaglandin E2HumansIntensive care medicineLH Lianhuaqingwen capsule030304 developmental biologyPharmacologyMedicinal herbMDA malondialdehydeGCGJ Gancao ganjiang decoctionNO nitric oxidePlants Medicinalbusiness.industrySARS-CoV-2COVID-19CXCL C-X-C- motif chemokineMDCK Madin-Darby Canine Kidney cellsTLR-4 Toll-like receptor-4COVID-19 Drug TreatmentComplementary and alternative medicineViral infectionLPS lipopolysaccharidesRSV respiratory syncytial virusQFPD Qingfeipaidu decoctionbusinessLung congestionECMO extracorporeal membrane oxygenationMAPK mitogen-activated protein kinasePhytotherapyDrugs Chinese HerbalPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Chromoendoscopy and Other Novel Imaging Techniques

2006

The newly developed high-resolution and magnification endoscopes offer features that allow more and new mucosal details to be seen. They are commonly used in conjunction with chromoendoscopy. The analysis of mucosal surface details is beginning to resemble histologic examination. More accurate recognition of small flat and depressed neoplastic lesions is possible. Endoscopic prediction of neoplastic and nonneoplastic tissue is possible by analysis of surface architecture of the mucosa, which influences the endoscopic management. For the diagnosis of flat adenomas, chromoendoscopy should be a part of the endoscopist's armamentarium. In inflammatory bowel disease, chromoendoscopy can be used …

Pathologymedicine.medical_specialtyColonoscopyMagnificationEndoscopic managementSensitivity and SpecificityMagnifying chromoendoscopyChromoendoscopyEndomicroscopymedicineHumansEnzyme InhibitorsClinical Trials as TopicIntraepithelial neoplasiaMicroscopy ConfocalStaining and Labelingmedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyImage EnhancementMethylene BlueChromogenic CompoundsColitis UlcerativeSurveillance colonoscopybusinessPrecancerous ConditionsTomography Optical CoherenceGastroenterology Clinics of North America
researchProduct

Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemo…

2014

An extensive number of pathologies are associated with mitochondrial dysfunction (MDF) and oxidative stress (OS). Thus, mitochondrial cofactors termed "mitochondrial nutrients" (MN), such as alpha-lipoic acid (ALA), Coenzyme Q10 (CoQ10), and L-carnitine (CARN) (or its derivatives) have been tested in a number of clinical trials, and this review is focused on the use of MN-based clinical trials. The papers reporting on MN-based clinical trials were retrieved in MedLine up to July 2014, and evaluated for the following endpoints: (a) treated diseases; (b) dosages, number of enrolled patients and duration of treatment; (c) trial success for each MN or MN combinations as reported by authors. The…

Pathologymedicine.medical_specialtyMitochondrial Diseasesmitochondrial nutrientsCoenzymesoxidative phosphorylationReviewPharmacologyMitochondrionBiologyControlled studiesmedicine.disease_causeChemopreventionCatalysislcsh:ChemistryInorganic Chemistrychemistry.chemical_compoundmitochondrial dysfunctionmedicineAnimalsHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopyCoenzyme Q10Clinical Trials as TopicOrganic ChemistryGeneral Medicine3. Good healthComputer Science ApplicationsMitochondriaClinical trialOxidative Stresslcsh:Biology (General)lcsh:QD1-999chemistrymitochondrial dysfunction and oxidative streKrebs cycleOxidative stressmitochondrial nutrient
researchProduct

Erythropoietin and subarachnoid hemorrhage.

2010

Pathologymedicine.medical_specialtySubarachnoid hemorrhageErytTime Factorserythropoietin subarachnoid hemorragelaw.inventionAnimals; Brain Ischemia; Clinical Trials; Phase II as Topic; Disease Models; Animal; Eryt; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recombinant Proteins; Subarachnoid Hemorrhage; Time Factors; hropoietinBrain IschemiaBrain ischemialawmedicineAnimalsHumansClinical TrialsRandomized Controlled Trials as TopicSettore MED/27 - Neurochirurgiabusiness.industryAnimalPhase II as TopicGeneral MedicinehropoietinSubarachnoid Hemorrhagemedicine.diseaseRecombinant ProteinsNeuroprotective AgentsErythropoietinDisease ModelsRecombinant DNAbusinessmedicine.drug
researchProduct

Usual Care and Informed Consent in Clinical Trials of Oxygen Management in Extremely Premature Infants

2016

Objective The adequacy of informed consent in the Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT) has been questioned. SUPPORT investigators and publishing editors, heads of government study funding agencies, and many ethicists have argued that informed consent was adequate because the two oxygen saturation target ranges studied fell within a range commonly recommended in guidelines. We sought to determine whether each oxygen target as studied in SUPPORT and four similar randomized controlled trials (RCTs) was consistent with usual care. Design/Participants/Setting PubMed, EMBASE, Web of Science, and Scopus were searched for English articles back to 1990 providi…

PediatricsComparative Effectiveness ResearchAlternative medicinePsychological interventionlcsh:MedicineNeonatal Carelaw.inventionDatabase and Informatics Methods0302 clinical medicineRandomized controlled triallawInformed consentMedicine and Health Sciences030212 general & internal medicineOximetryDatabase Searchinglcsh:ScienceRandomized Controlled Trials as TopicMultidisciplinarymedicine.diagnostic_testHospitalsInformed Consent By MinorsChemistryIntensive Care UnitsResearch DesignInfant Extremely PrematurePhysical SciencesResearch ArticleChemical ElementsAdultmedicine.medical_specialtyDrug Research and DevelopmentClinical Research DesignDeath RatesComparative effectiveness researchResearch and Analysis Methods03 medical and health sciencesPopulation Metrics030225 pediatricsmedicineHumansClinical TrialsIntensive care medicineOxygen saturationDemographyPharmacologyPopulation Biologybusiness.industrylcsh:RInfant NewbornBiology and Life SciencesRandomized Controlled TrialsClinical trialOxygenHealth CarePulse oximetryHealth Care FacilitiesPeople and PlacesIntensive Care Neonatallcsh:QClinical MedicinebusinessPLoS ONE
researchProduct

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

2019

Purpose of Review Familial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With “central support,” more centers and countries participated in the project. Subsequently, individ…

Pediatricsmedicine.medical_specialtyInternational CooperationFamilial hypercholesterolemiaFamilial hypercholesterolemia030204 cardiovascular system & hematologyTreatment resultsAntibodies Monoclonal HumanizedFHHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineTotal cholesterolmedicineHumansMass ScreeningEffective treatment030212 general & internal medicineScreenPro FHLDL-CAlirocumabInternational networkEvidence-Based Medicine Clinical Trials and Their Interpretations (L. Roever Section Editor)business.industryAnticholesteremic AgentsIncidencePCSK9 InhibitorsScreen and treatmedicine.diseaseEvolocumab3. Good healthEuropeEvolocumabProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessDelivery of Health CareAlirocumabCurrent Atherosclerosis Reports
researchProduct